Mutations in the transcriptional repressor REST predispose to Wilms tumor

[1]  Michael T. Rock.  Lessons for the Rest , 2016 .

[2]  S. Seal,et al.  The ICR1000 UK exome series: a resource of gene variation in an outbred population , 2015, F1000Research.

[3]  Kathy Pritchard-Jones,et al.  The yin and yang of kidney development and Wilms’ tumors , 2015, Genes & development.

[4]  C. Shaw,et al.  The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. , 2014, Cell reports.

[5]  S. Seal,et al.  Germline mutations in the PAF1 complex gene CTR9 predispose to Wilms tumour , 2014, Nature Communications.

[6]  G. McVean,et al.  Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications , 2014, Nature Genetics.

[7]  David A. Bennett,et al.  REST and Stress Resistance in Aging and Alzheimer’s Disease , 2014, Nature.

[8]  Peter Donnelly,et al.  Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer , 2012, Nature.

[9]  Martin Goodson,et al.  Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. , 2011, Genome research.

[10]  A. Bithell.  REST: transcriptional and epigenetic regulator. , 2011, Epigenomics.

[11]  U Schumacher,et al.  Regulation of the NRSF/REST gene by methylation and CREB affects the cellular phenotype of small-cell lung cancer , 2010, Oncogene.

[12]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[13]  Rory Johnson,et al.  The role of REST in transcriptional and epigenetic dysregulation in Huntington's disease , 2010, Neurobiology of Disease.

[14]  Xavier Estivill,et al.  DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome. , 2008, American journal of human genetics.

[15]  I. Wood,et al.  Chromatin crosstalk in development and disease: lessons from REST , 2007, Nature Reviews Genetics.

[16]  N. Rahman,et al.  Surveillance for Wilms tumour in at-risk children: pragmatic recommendations for best practice , 2006, Archives of Disease in Childhood.

[17]  N. Rahman,et al.  Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour , 2006, Journal of Medical Genetics.

[18]  J. Haefliger,et al.  IB1/JIP-1 controls JNK activation and increased during prostatic LNCaP cells neuroendocrine differentiation. , 2005, Cellular signalling.

[19]  G. Mandel,et al.  REST and Its Corepressors Mediate Plasticity of Neuronal Gene Chromatin throughout Neurogenesis , 2005, Cell.

[20]  N. Rahman,et al.  Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Becker,et al.  Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor α1 subunit in small-cell lung cancer cells , 2003, Oncogene.

[22]  N. Rahman,et al.  Evidence for susceptibility genes to familial Wilms tumour in addition to WT1, FWT1 and FWT2 , 2000, British Journal of Cancer.

[23]  L. Strong,et al.  Linkage of familial Wilms' tumor predisposition to chromosome 19 and a two-locus model for the etiology of familial tumors. , 1998, Cancer research.

[24]  Nazneen Rahman,et al.  Evidence for a familial Wilms' tumour gene (FWT1) on chromosome 17q12–q21 , 1996, Nature Genetics.